Acadia Pharmaceuticals shares are trading lower after the company reported the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia did not meet the primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
Acadia Pharmaceuticals' stock is trading lower following the announcement that its Phase 3 ADVANCE-2 trial of pimavanserin for treating negative symptoms of schizophrenia failed to meet the primary endpoint.
March 11, 2024 | 8:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Acadia Pharmaceuticals' shares are down after its schizophrenia treatment trial did not meet the primary endpoint.
The failure of the Phase 3 ADVANCE-2 trial is a significant setback for Acadia Pharmaceuticals, as successful trial results could have led to a new revenue stream from pimavanserin. This news directly impacts the company's potential future earnings and growth prospects, leading to a negative short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100